Clinical Trials & Research Studies Near You (Updated 5/25)

The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)

NCT04855396

Recruiting

There are no therapeutic agents that have been shown to improve outcomes from severe traumatic brain injury (TBI). Critical barriers to progress in developing treatments for severe TBI are the lack of: 1) monitoring biomarkers for assessing individual patient response to treatment; 2) predictive biomarkers for identifying patients likely to benefit from a promising intervention. Currently, clinical examination remains the fundamental tool for monitoring severe TBI patients and for subject select... Read More

There are no therapeutic agents that have been shown to improve outcomes from severe traumatic brain injury (TBI). Critical barriers to progress in developing treatments for severe TBI are the lack of: 1) monitoring biomarkers for assessing individual patient response to treatment; 2) predictive biomarkers for identifying patients likely to benefit from a promising intervention. Currently, clinical examination remains the fundamental tool for monitoring severe TBI patients and for subject selection in clinical trials. However, these patients are typically intubated and sedated, limiting the utility of clinical examinations. Validated monitoring and predictive biomarkers will allow titration of the dose of promising therapeutics to individual subject response, as well as make clinical trials more efficient by enabling the enrollment of subjects likely to benefit. Glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL) and high sensitivity c-reactive protein (hsCRP) are promising biomarkers that may be useful as 1) monitoring biomarkers; 2) predictive biomarkers in severe TBI trials. Although the biological rationale supporting their use is strong, significant knowledge gaps remain. To address these gaps in knowledge, we propose an ancillary observational study leveraging an ongoing severe TBI clinical trial that is not funded to collect biospecimen. The Hyperbaric Oxygen in Brain Injury Treatment (HOBIT) trial, a phase II randomized control clinical trial that seeks to determine the dose of hyperbaric oxygen therapy (HBOT) that that has the highest likelihood of demonstrating efficacy in a phase III trial. The proposed study will: 1) validate the accuracy of candidate monitoring biomarkers for predicting clinical outcome; 2) determine the treatment effect of different doses of HBOT on candidate monitoring biomarkers; and 3) determine whether there is a biomarker defined subset of severe TBI that responds favorably to HBOT. This proposal will: 1) inform a go/no-go decision for a phase III trial of HBOT by providing adjunctive evidence of the effect of HBOT on key biological pathways through which HBOT is hypothesized to affect outcome; 2) provide evidence to support further study of the first monitoring biomarkers of severe TBI; 3) increase the likelihood of success of a phase III trial by identifying the sub-population of severe TBI likely to benefit from HBOT; 4) create a repository of TBI biospecimen which may be accessed by other investigators. This study is related to NCT04565119 Read Less

Gender:

ALL

Ages:

Between 16 years and 65 years

Trial Updated:

03/31/2025

Locations: UCSD Medical Center - Hillcrest Hospital, San Diego, California +10 locations

Conditions: Traumatic Brain Injury

Register for Updates

Learn More ›

Adaptive Optics Imaging of Outer Retinal Diseases

NCT05355415

Recruiting

The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.

Gender:

ALL

Ages:

21 years and above

Trial Updated:

03/31/2025

Locations: NIH Clinical Center, Bethesda, Maryland +1 locations

Conditions: Retinal Degeneration, Age-Related Macular Degeneration, Retinitis Pigmentosa, Hydroxychloroquine Retinopathy, Usher Syndromes, Late-Onset Retinal Degeneration, Cone Dystrophy, Cone Rod Dystrophy, Rod Cone Dystrophy, Rod Dystrophy

Register for Updates

Learn More ›

The ECMO-Free Trial

NCT05486559

Recruiting

Decannulation from venovenous extracorporeal membrane oxygenation (VV-ECMO) at the earliest and safest time would be expected to improve outcomes and reduce cost. Daily assessments for readiness to liberate from therapies have demonstrated success in other realms of critical care. A recent single-center study demonstrated that a protocolized daily assessment of readiness for liberation from VV-ECMO was feasible and did not raise any major safety concerns, but the effect of this protocolized dail... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/31/2025

Locations: Hennepin County Medical Center, Minneapolis, Minnesota +1 locations

Conditions: Extracorporeal Membrane Oxygenation Complication

Register for Updates

Learn More ›

NIBP Validation Study

NCT05673408

Recruiting

The purpose of this study is to compare measurements of blood pressure (BP) between the Philips non-invasive blood pressure (NIBP) system (including NIBP cuff and portable patient monitor) and invasive radial arterial line (A-line) in critical care patients.

Gender:

ALL

Ages:

All

Trial Updated:

03/31/2025

Locations: Mayo Clinic Jacksonville, Jacksonville, Florida +4 locations

Conditions: Critical Illness

Register for Updates

Learn More ›

StuDy AimED at Increasing AlCohol AbsTinEnce

NCT05778734

Recruiting

The goal of this clinical trial is to test the feasibility \& acceptability of an integrated CM-PST intervention (in K99 phase) and preliminary efficacy (in R00 phase), vs. CM alone, to improve treatment efficacy and inform about neural mechanisms of treatment effects in young adults with Alcohol Use Disorder (AUD). The aims are as follows: K99 Aim: Test feasibility \& acceptability of a developed CM-PST, by meeting these benchmarks: 2a Feasibility: enroll 20 participants in the new CM-PST in... Read More

Gender:

ALL

Ages:

Between 18 years and 24 years

Trial Updated:

03/31/2025

Locations: University of Illinois at Chicago, Chicago, Illinois

Conditions: Alcohol Use Disorder

Register for Updates

Learn More ›

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773

Recruiting

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/31/2025

Locations: Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada +113 locations

Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada

Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson, Henderson, Nevada

Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie, Henderson, Nevada

Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II, Las Vegas, Nevada

Comprehensive Cancer Centers of Nevada - Southwest, Las Vegas, Nevada

Comprehensive Cancer Centers of Nevada - Central Valley - Twain, Las Vegas, Nevada

Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada

Gabrail Cancer and Research Center, Canton, Ohio

The Toledo Clinic Cancer Center, Toledo, Ohio

University of Texas MD Anderson Cancer Center, Houston, Texas

Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Flemish Brabant

Algemeen Ziekenhuis Maria Middelares, Gent, Oost-Vlaaderen

Algemeen Ziekenhuis Delta - Campus Menen, Menen, West Flanders

Algemeen Ziekenhuis Delta - Campus Rumbeke, Rosières, West-Vlaanderen

Centro Regional Integrado de Oncologia, Fortaleza, Ceará

Hospital São Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul

Clínica Neoplasias Litoral, Itajaí, Santa Catatina

Hospital Amaral Carvalho, Jaú, São Paulo

Multi-profile Hospital for Active Treatment Uni Hospital, Panagyurishte, Pazardzhik

University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna-ISUL, Sofia, Not set

William Osler Health System - Brampton Civic Hospital, Brampton, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

Les Hôpitaux Universitaires de Strasbourg, Strasbourg cedex, Alsace

Hôpital Côte De Nacre, Caen cedex 9, Basse-Normandie

Institut Curie, Paris cedex, Ile-de-France

Centre Hospitalier Universitaire Limoges, Limoges, Limousin

Hôpital Haut-Lévêque, Pessac, Nouvelle-Aquitaine

Centre Hospitalier Le Mans, Le Mans cedex 9, Pays De La Loire

Gustave Roussy, Villejuif, Val-de-Marne

Hôpital Ambroise-Paré, Boulogne-Billancourt, Île-de-France

Asklepios Klinik Altona, Hamburg, Hamburg (Hansestadt)

Universitätsklinikum Gießen und Marburg - Gießen, Gießen, Hessen

LMU Klinikum - Campus Innenstadt, München, Not set

Universitätsklinikum Regensburg, Regensburg, Not set

General Hospital for Thoracic Diseases Sotiria, Athens, Attica

Metropolitan General, Piraeus, Attica

University General Hospital of Patras, Patra, Peloponnese

Metropolitan Hospital, Peiraias, Pireas

University General Hospital of Larissa, Larissa, Thessaly

BioClinic Thessaloniki, Thessaloniki, Not set

Emek Medical Center, Afula, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Hadassah University Hospital Ein Kerem, Jerusalem, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

Assuta Hospital - Ramat HaHayal, Tel aviv, Not set

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Forlì-Cesena

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele, Milan, Not set

Azienda Ospedaliero - Universitaria di Modena, Modena, Not set

Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

Azienda Unità Sanitaria Locale della Romagna, Ravenna, Not set

Azienda Ospedaliera Universitaria Integrata Verona, Verona, Not set

Aichi Cancer Center, Nagoya, Aiti [Aichi]

Hirosaki University Hospital, Hirosaki-Shi, Aomori

Kyushu Cancer Center, Fukuoka-shi, Hukuoka

Kitasato University Hospital, Sagamihara, Kanagawa

Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa

Saiseikai Kumamoto Hospital, Kumamoto-Shi, Kumamoto

Sendai Kousei Hospital, Sendai, Miyagi

Okayama University Hospital, Okayamashi, Okayama

Kansai Medical University Hospital, Hirakata, Osaka

National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai-Shi, Osaka

Cancer Institute Hospital of JFCR, Koto, Tokyo

Keio University Hospital, Shinjuku-Ku, Tokyo

Kanazawa University Hospital, Kanazawa, Not set

Osaka City General Hospital, Osaka, Not set

Osaka Prefectural Hospital Organization - Osaka International Cancer Institute, Osaka, Not set

Catholic University of Korea Saint Vincent's Hospital, Suwon-si, Gyeonggi-do

Ajou University Hospital, Suwon-si, Gyeonggi-do

Gyeongsang National University Hospital, Jinju, Gyeongsangnamdo [Kyongsangnam-do]

Inha University Hospital, Incheon, Incheon Gwang'yeogsi [Inch'on-Kwangyokshi]

Korea University Anam Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Korea University Guro Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Clínica Integral Internacional de Oncología S de RL de CV, Mirador, Puebla

FAICIC Clínical Research, Veracruz, Not set

Radboud Universitair Medisch Centrum, Nijmegen, Gelderland

Vrije Universiteit Medisch Centrum, Amsterdam, Noord-Holland

St. Luke's Medical Center - Quezon City, Quezon City, Metropolitan Manila

Asian Hospital and Medical Center, Muntinlupa, Not set

Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Lubelskie

Instytut MSF, Łódź, Lódzkie

Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów, Pozna?, Wielkopolskie

Medisprof, Cluj-Napoca, Cluj

Centrul de Oncologie Sf Nectarie, Craiova, Dolj

Oncocenter - Oncologie Clinica, Timişoara, Timis

Clinica SIGMedical, Suceava, Not set

Icon Cancer Centre - Mount Alvernia, Singapore, Not set

Tan Tock Seng Hospital, Singapore, Not set

Oncocare Cancer Centre, Singapore, Not set

Icon Cancer Centre Mount Elizabeth, Singapore, Not set

Complejo Hospitalario Universitario A Coruña, A Coruña, La Coruña

Clínica Mi Tres Torres, Barcelona, Not set

Hospital Quirónsalud Barcelona, Barcelona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital Universitario de Jaén, Jaén, Not set

MD Anderson Cancer Center Madrid, Madrid, Not set

Hospital Universitario Fundación Jiménez Díaz, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Regional Universitario de Málaga - Hospital General, Málaga, Not set

Faculty of Medicine Siriraj Hospital, Bang Phlat, Bangkok

King Chulalongkorn Memorial Hospital, Pathum Wan, Bangkok

Navamindradhiraj University - Faculty of Medicine Vajira Hospital, Krung Thep Maha Nakhon, Khet Dusit

T.C. Saglik Bakanligi Adana Sehir Egitim ve Arastirma Hastanesi, Adana, Not set

Medical Park Seyhan Hastanesi, Adana, Not set

Hacettepe Üniversitesi Kanser Enstitüsü, Ankara, Not set

Memorial Ankara Hastanesi, Ankara, Not set

Trakya Üniversitesi Sa?l?k Ara?t?rma ve Uygulama Merkezi, Edirne, Not set

Ankara Il Saglik Mudurlugu SBU Gulhane Egitim Ve Arastirma Hastanesi, Etlik, Not set

Bagcilar Medipol Mega Universite Hastanesi, Istanbul, Not set

T.C. Saglik Bakanligi - Istanbul Il Saglik Mudurlugu - Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, Not set

T.C. Saglik Bakanligi Ankara Bilkent Sehi?r Hastanesi?, Çankaya, Not set

Royal Free London NHS Foundation Trust, London, England

Nottingham University Hospitals NHS Trust, Nottingham, England

Torbay and South Devon NHS Foundation Trust, Torquay, England

Conditions: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

Register for Updates

Learn More ›

Hypotensive Anesthesia for Orthognathic Surgery

NCT06093893

Recruiting

The overall objective of this double blinded, randomized controlled trial (RCT) is to compare specific outcomes of three medications (Dexmedetomidine, Nicardipine, and Labetalol) which are routinely used to lower blood pressure used during general anesthesia for orthognathic (jaw) surgery. The outcome measures for the study will be surgical field visibility, estimated blood loss, hemodynamic parameters, operation time, and adverse events. The specific objectives of this study are to compare: 1... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/31/2025

Locations: Boston Medical Center, Boston, Massachusetts

Conditions: Hypotensive Anesthesia, Orthognathic Surgery

Register for Updates

Learn More ›

Genomic Medicine Risk Assessment Care for Everyone - Implementation Phase

NCT06278883

Recruiting

The "Genomic medicine Risk Assessment Care for Everyone" (GRACE)" intervention project will develop a scalable end-to-end solution for risk assessment and management that meets the needs of those populations living in low resource settings. The long-term goal is to increase access to and uptake of risk-informed evidence-based guidelines that will improve population health through better patient outcomes, higher quality of life, and decreased costs. The three primary aims are: Aim 1: Develop a s... Read More

The "Genomic medicine Risk Assessment Care for Everyone" (GRACE)" intervention project will develop a scalable end-to-end solution for risk assessment and management that meets the needs of those populations living in low resource settings. The long-term goal is to increase access to and uptake of risk-informed evidence-based guidelines that will improve population health through better patient outcomes, higher quality of life, and decreased costs. The three primary aims are: Aim 1: Develop a scalable implementation framework that guides each unique clinical setting, including low resource settings, in deploying GRACE effectively for the needs of their patients and providers. Aim 2: Facilitate the potential for genomic medicine to promote population health by broadening access to and uptake of genomic risk assessment by the general population through a pragmatic implementation-effectiveness trial of GRACE. Aim 3: Reduce health disparities related to genomic medicine by allowing individual adaption of GRACE to suit their level of resources, education, and access within a pragmatic implementation-effectiveness trial. Three sets of participants will be engaged: patients (n=750), providers (n=25), and family members of "probands" (i.e., patients that have a genetic change that increases risk, n\~500). Patient participants will be asked to complete a baseline survey, enter their family health history information into MeTree (a family health history web-based platform) and complete a survey about their experience using the platform. Subsequent study procedures will depend on: 1) the results of their MeTree risk evaluation, 2) their acceptance/declination of genetic testing (for those categorized as needing testing by MeTree), and 3) the results of the test (for those accepting testing). Provider participants will be providers who are the primary care physicians treating one or more patients enrolled in the patient participant group. Providers will be notified on a patient by patient basis once the patient participant under their care has complete the risk assessment process and the risk report is available from MeTree. At study completion, provider participants will be asked to complete a survey about their demographics, practice, and experiences with the study. Blood relatives of the probands who are identified by the proband as open to engaging with the study will be contacted and offered genetic counseling and genetic testing. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/31/2025

Locations: UF Health Family Medicine - Lem Turner, Jacksonville, Florida +3 locations

Conditions: Cardiovascular Diseases, Cancer, Liver Diseases, Hyperthermia

Register for Updates

Learn More ›

Acellular Dermal Matrix Investigation in Breast Reconstruction

NCT06456554

Recruiting

Prospective, multi-center, dual-arm non-randomized clinical study in females undergoing a two-stage breast reconstruction using a pre-pectoral technique.

Gender:

FEMALE

Ages:

22 years and above

Trial Updated:

03/31/2025

Locations: University of Colorado, Aurora, Colorado +5 locations

Conditions: Breast Reconstruction

Register for Updates

Learn More ›

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

NCT06630286

Recruiting

The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard treatment of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with human immunodeficiency virus (PWH) who are virologically suppressed (HIV-1 RNA levels \< 50 copies/mL) on B/F/TAF for ≥ 6 months prior to screening. The primary objective is to evaluate the efficacy of switching to oral weekly ISL/LE... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/31/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +105 locations

University of Alabama at Birmingham, Birmingham, Alabama

Pueblo Family Physicians, Phoenix, Arizona

Kaiser Permanente Southern California, Los Angeles, California

Ruane Clinical Research Group, Inc, Los Angeles, California

Mills Clinical Research, Los Angeles, California

BIOS Clinical Research, Palm Springs, California

Optimus Medical Group, San Francisco, California

Vivent Health, Denver, Colorado

University of Colorado- Anschutz Medical Campus - PPDS, Denver, Colorado

Yale University, New Haven, Connecticut

Georgetown University, Washington, District of Columbia

Whitman-Walker Health, Washington, District of Columbia

CAN Community Health, Fort Lauderdale, Florida

Midway Immunology and Research Center, Fort Pierce, Florida

CAN Community Health, Miami Gardens, Florida

Midland Research Group, Inc., Oakland Park, Florida

Orlando Immunology Center, Orlando, Florida

AHF (AIDS Healthcare Foundation) - Pensacola Research, Pensacola, Florida

CAN Community Health, Sarasota, Florida

St. Josephs Comprehensive Research Institute, Tampa, Florida

Emory University, Atlanta, Georgia

Infectious Disease Specialists of Atlanta, Decatur, Georgia

Mercer University, Macon, Georgia

Chatham CARE Center, Savannah, Georgia

Howard Brown Health, Chicago, Illinois

Indiana University School of Medicine, Indianapolis, Indiana

The Brigham and Women's Hospital, Inc., Boston, Massachusetts

Boston Medical Center, Boston, Massachusetts

Community Research Initiative, Boston, Massachusetts

Be Well Medical Center, Berkley, Michigan

Trinity Health, Grand Rapids, Michigan

KC CARE Health Center, Kansas City, Missouri

ID CARE, Hillsborough, New Jersey

Saint Michael's Medical Center, Newark, New Jersey

South Jersey Infectious Disease, Somers Point, New Jersey

AXCES Research Group - Albuquerque, Santa Fe, New Mexico

Jacobi Medical Center, Bronx, New York

Montefiore Medical Center, Bronx, New York

Brooklyn Clinical Research Center, Brooklyn, New York

New York Presbyterian Hospital, Flushing, New York

CTRC University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Atrium Health Infectious Disease Kenilworth, Charlotte, North Carolina

Duke University, Durham, North Carolina

Brody School of Medicine at East Carolina University Adult Specialty Care, Greenville, North Carolina

Rosedale Health and Wellness, Huntersville, North Carolina

University of Cincinnati, Cincinnati, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Ohio State University, Columbus, Ohio

Prisma Health/USC, Columbia, South Carolina

Central Texas Clinical Research, Austin, Texas

North Texas Infectious Diseases Consultants, Dallas, Texas

AXCES Research Group, LLC, El Paso, Texas

Texas Centers for Infectious Disease Associates, Fort Worth, Texas

The Crofoot Research Center, INC., Houston, Texas

DCOL Center for Clinical Research, Longview, Texas

AXCES Research Group, LLC, Salt Lake City, Utah

Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID), Annandale, Virginia

Peter Shalit MD, Seattle, Washington

MultiCare Institute for Research & Innovation, Spokane, Washington

University of Wisconsin-Madison, Madison, Wisconsin

Fundacion Huesped, Buenos Aires, Not set

Helios Salud S.A., Buenos Aires, Not set

East Sydney Doctors, Darlinghurst, New South Wales

St Vincent's Hospital, Darlinghurst, New South Wales

Taylor Square Private Clinic, Surry Hills, New South Wales

Monash Health, Clayton, Victoria

Prahran Market Private Clinic, South Yarra, Victoria

Clinique de médecine Urbaine du Quartier Latin, Montreal, Not set

McGill University Health Centr, Montreal, Not set

Spectrum Health, Vancouver, Not set

CHU Bordeaux - Hopital Saint André, Bourdeaux, Not set

AP-HP-Hopital Bicétre, Le Kremlin Bicetre, Not set

Assistance Publique Hopitaux de Marseille - Hopital Sainte Marguerite, Marseile, Not set

CHU Nice - Hopital Archet I, Nice, Not set

EPIMED GmbHGesellschaft fur klinische und epidemiologische Forschung in Berlin, Berlin, Not set

University Hospital Bonn, Medizinische und Poliklink I, Immunologische Studienambulanz, Bonn, Not set

Universitatsmedizin Essen, Universitatsklinikum Essen, Klinik Dermatologie, Venerologie und Allergologie,, HPSTD-Ambulanz, Essen, Not set

ICH Study Center GmbH & Co.KG, Hamburg, Not set

Uniklinik Kéin, Innere Medizin |, Klinisches Studienzentrum Infektiologle, Clinical Trials Unit for Infectious Diseases(CTU-ID), ISZ Geb. 80, Köln, Not set

Chiba University Hospital, Chiba, Not set

National Hospital Organization Nagoya Medical Center, Nagoya, Not set

University of the Ryukyus Hospital, Okinawa, Not set

National Hospital Organization Osaka National Hospital, Osaka Fu, Not set

Osaka City General Hospital, Osaka-City, Not set

Tokyo Medical University Hospital, Tokyo, Not set

National Center for Global Health and Medicine, Tokyo, Not set

Clinical Research Puerto Rico, San Juan, Not set

University of Puerto Rico School of Medicine, San Juan, Not set

Hospital Universitario Vall d' Hebron, Barcelona, Not set

Hospital Clinic Barcelona, Barcelona, Not set

Complexo Hospitalario Universitario da Coruna, La Coruña, Not set

Hospital Universitario Regional de Malaga, Málaga, Not set

Inselspital, Bern, Not set

Centre Hospitalier Universitaire Vaudois, Lausanne, Not set

Universitaetsspital Zuerich, Zurich, Not set

Kaohsuing Medical University Hospital, Kaohsiung, Not set

Kaohsuing Veterans General Hospital, Kaohsiung, Not set

Far Eastern Memorial Hospital, New Taipei City, Not set

National Taiwan University Hospital, Taipei City, Not set

Taoyuan General Hospital, Taoyuan City, Not set

Hawthorn House, Birmingham Heartlands Hospital (University Hospitals Birmingham NHS Foundation Trust), Birmingham, Not set

Clinical Research Facility (University Hospitals Sussex NHS Foundation Trust), Brighton, Not set

Grahame Hayton Unit, Ambrose King Centre, Royal London Hospital (Barts Health NHS Trust), London, Not set

Royal Free Hospital (Royal Free London NHS Foundation Trust), London, Not set

Clinical Research Facility, 1st Floor, St Stephen's Centre, Chelsea and Westminster Hospital (Chelsea and Westminster Hospital NHS Foundation Trust), London, Not set

Mortimer Market Centre (Central and North West London NHS Foundation Trust), London, Not set

Conditions: HIV-1-infection

Register for Updates

Learn More ›

Improving Sympathetic Activity, Hot Flashes, and Sleep in Midlife Women Using Inspiratory Muscle Strength Training

NCT06743269

Recruiting

The purpose of this research is to understand how training the muscles used for breathing (inhalation) affects menopausal hot flashes, sympathetic nerve activity and sleep.

Gender:

FEMALE

Ages:

Between 45 years and 60 years

Trial Updated:

03/31/2025

Locations: Mayo Clinic in Rochester, Rochester, Minnesota

Conditions: Menopause, Hot Flashes, Blood Pressure Regulation

Register for Updates

Learn More ›

Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa

NCT06849830

Recruiting

The goal of this clinical trial is to evaluate whether a narrative medicine (NM) curriculum can enhance self-expression, reflection, and resilience in adolescents and young adults with anorexia nervosa. The main questions it aims to answer are: * Does participation in an NM curriculum improve self-expression and reflection in individuals with anorexia nervosa? * Does engaging in creative writing and group discussion promote resilience and emotional processing in this population? Participants... Read More

Gender:

ALL

Ages:

Between 16 years and 25 years

Trial Updated:

03/31/2025

Locations: UCSF Nancy Friend Pritzker Psychiatry Building, San Francisco, California

Conditions: Anorexia Nervosa

Register for Updates

Learn More ›

All Clinical Trials

Match to Clinical Trials